2. Academic Validation
  3. Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors

Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors

  • Bioorg Med Chem Lett. 2003 Dec 15;13(24):4365-9. doi: 10.1016/j.bmcl.2003.08.080.
Patrick Angibaud 1,  Xavier Bourdrez,  David W End,  Eddy Freyne,  Michel Janicot,  Patricia Lezouret,  Yannick Ligny,  Geert Mannens,  Siegrid Damsch,  Laurence Mevellec,  Christophe Meyer,  Philippe Muller,  Isabelle Pilatte,  Virginie Poncelet,  Bruno Roux,  Gerda Smets,  Jacky Van Dun,  Pieter Van Remoortere,  Marc Venet,  Walter Wouters
Affiliations

Affiliation

  • 1 Medicinal Chemistry Department Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), Campus de Maigremont BP615, 27106, Val de Reuil, France. [email protected]
PMID: 14643327 DOI: 10.1016/j.bmcl.2003.08.080
Abstract

A series of (4-chlorophenyl)-alpha-(1-methyl-1H-imidazol-5-yl)azoloquinolines and -quinazolines was prepared. These compounds displayed potent Farnesyl Protein Transferase inhibitory activity and tetrazolo[1,5-a]quinazolines are promising agents for oral in vivo inhibition.

Figures